Israel’s AEYE Health (reported previously) is pushing hard to get its retinal disease AI diagnostic eye scanner approved by the end of 2020. The Covid-19 pandemic has seriously cut the number of patients visiting eye specialists. The eye scanner can be used easily by GPs or clinic staff.
Israeli biotech Mileutis has developed Imilac - designed to treat mastitis in cows by boosting their immune systems. Imilac is near the marketing stage and can replace the wide use of antibiotics for which resistance is growing and being passed to humans via milk products.
Nanotechnologists at Israel’s Technion Institute have eliminated the time-consuming amplification process in coronavirus and secondary cancer tests. 100 molecules of the sample are passed one by one through a nanopore – a tiny hole and assessed for the presence of a specific bio-marker.
Israel’s Adasky (reported previously) develops and manufactures high-resolution thermal vision AI sensors for the advanced vehicle industry. Its Viper-R system can detect Covid-19 instantly, by scanning multiple individuals 10 meters away for elevated body temperatures.
Israel’s NextGen Biomed is developing a breathalyzer test to identify Covid-19 infections. The biological markers were identified in an April study by Israel’s Scentech Medical. The two companies are now being merged and a validation trial is scheduled to commence shortly.
Israel Aidoc’s triaging and notification algorithms for flagging and reporting incidental pulmonary embolism have just been approved by the US FDA. The solution is an ‘always-on’ safety net for unexpected cases. It is Aidoc’s sixth FDA-approved tool for triage and notification:
Ziv Medical Center in Tzfat (Safed) will be the first Israeli hospital to use drones. They will transport medical equipment, medicines, and blood and Corona tests, to and from the hospital. Initially, they will carry 5kg loads up to 10km, saving time and bypassing road blockages.
Israel’s Kamada (reported previously) has signed a deal to supply Israel’s Health ministry with its plasma-based hyperimmune immunoglobulin (IgG) product. The product treats COVID-19 patients with pneumonia and is currently in Phase 1 & 2 trials in Israel.
The Covid-19 vaccine being developed by the Israel Institute for Biological Research (IIBR) is beginning Phase 1 human trials. Head of IIBR, Professor Shapira confirmed this at the recent Christian Media zoom Summit attended by this newsletter editor, who asked a question at 1:38:47.
Israeli biotech Nasus has developed the Taffix anti-viral nasal spray. It creates a thin gel over the nasal mucosa, blocking viruses for 4-5 hours. In recent tests, Taffix reduced Covid-19 infections from 10% down to 2.4%. Taffix is marketed in Europe and available at SuperPharm in Israel.